Novo Nordisk
12 articles · Jan 2026 — Feb 2026
Summary being generated — check back shortly.
Coverage Timeline 6 articles
Big Pharma Partners with Innovators to Tackle Chronic Diseases
Novo Nordisk and Merck team up with startups and hospitals to develop new treatments
Trump Administration Faces Multiple Challenges on Tariffs, Postal Service, and Iran
Novo Nordisk slashes prices, FedEx sues for refund, and Supreme Court shields Postal Service from lawsuits
Ozempic and Wegovy Pills Raise New Concerns Over Gut Health
Study finds hidden ingredient may alter gut bacteria and inflammation
Pharma Giants Make Big Moves in Separate Deals
Gilead Sciences is buying Arcellx for $7.8 billion, expanding its CAR-T therapy portfolio, while Novo Nordisk's next-gen obesity drug underperformed in a comparison study.
Hims & Hers to Stop Selling Compounded Obesity Pill Amid Regulatory Scrutiny and Other Health Controversies
Telehealth company Hims & Hers will cease sales of its compounded version of Novo Nordisk's obesity pill, Wegovy, following a request by the US Department of Health and Human Services (HHS) for the Justice Department to probe the company's practices. This development comes amidst a broader landscape of controversy in healthcare, including debates over gender-affirming care, concerns about the integrity of medical research, and scrutiny of pharmaceutical pricing.
Biotech Roundup: New Launches, Leadership Changes, and Advances in Medical Devices
The biotech industry is abuzz with new developments, from the US launch of Novo Nordisk's Wegovy pill to leadership changes at Argenx. Meanwhile, Neuralink is making waves in the field of brain implants, but not everyone is convinced of its intentions. Here's a rundown of the latest news and trends in the biotech sector.